⌘K
Loading ticker…
As of 2026-08-24, Nuvectis Pharma, Inc. Common Stock (NVCT) has a 3-month relative strength percentile of 98 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 95. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.5%, relative volume 1.09×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
NVCT is in a stage 2 uptrend, week 12. Currently in a 39-day base; basing ADR 7.3% (broad 7.2%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 22.1% / 113.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
NVCT is held by 9 ETFs as of May 2026. Top owner: VTWO at 0.00% weight, $777K notional. Top 3 carry $1M.
Held by 15 ETFs · $10M across latest filings · largest weight 0.02% (IWC).
Top 9 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $6K |
| — |
| UWM | 0.00% | $6K | — |
| HDG | 0.00% | $137 | — |
| RB | 0.00% | $39 | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCT Jan avg: 13.01% median: 16.19% win: 75% σ: 20.00% n: 4 2022-04-12 → 2026-07-31 | NVCT Feb avg: 14.71% median: 12.23% win: 75% σ: 15.34% n: 4 2022-04-12 → 2026-07-31 | NVCT Mar avg: 7.77% median: 0.97% win: 50% σ: 29.12% n: 4 2022-04-12 → 2026-07-31 | NVCT Apr avg: -0.55% median: 1.94% win: 60% σ: 15.48% n: 5 2022-04-12 → 2026-07-31 | NVCT May avg: 19.24% median: 13.90% win: 80% σ: 23.58% n: 5 2022-04-12 → 2026-07-31 | NVCT Jun avg: 5.46% median: -8.74% win: 20% σ: 47.16% n: 5 2022-04-12 → 2026-07-31 | NVCT Jul avg: -4.59% median: -6.83% win: 40% σ: 14.45% n: 5 2022-04-12 → 2026-07-31 | NVCT Aug avg: -0.56% median: -1.95% win: 50% σ: 7.97% n: 4 2022-04-12 → 2026-07-31 (current) | NVCT Sep avg: -10.06% median: -9.78% win: 0% σ: 1.77% n: 4 2022-04-12 → 2026-07-31 | NVCT Oct avg: -1.18% median: 3.55% win: 50% σ: 21.84% n: 4 2022-04-12 → 2026-07-31 | NVCT Nov avg: -9.04% median: -6.02% win: 25% σ: 17.09% n: 4 2022-04-12 → 2026-07-31 | NVCT Dec avg: 7.12% median: 4.69% win: 75% σ: 9.99% n: 4 2022-04-12 → 2026-07-31 |